Spots Global Cancer Trial Database for dacarbazine
Every month we try and update this database with for dacarbazine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | NCT05404945 | Classical Hodgk... | Pembrolizumab Doxorubicin Vinblastine Dacarbazine Brentuximab ved... | 60 Years - | University of Virginia | |
| Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | NCT00110994 | Cancer Melanoma | Sorafenib (Nexa... Placebo Dacarbazine | 18 Years - | Bayer | |
| E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma | NCT01133977 | Stage IV Melano... | Lenvatinib Lenvatinib Dacarbazine | 18 Years - | Eisai Inc. | |
| Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease | NCT00000626 | HIV Infections Hodgkin's Disea... | Vinblastine sul... Dacarbazine Filgrastim Bleomycin sulfa... Doxorubicin hyd... | 12 Years - | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma | NCT01721772 | Melanoma | BMS-936558 (Niv... Placebo matchin... Dacarbazine Placebo matchin... | 18 Years - | Bristol-Myers Squibb | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | NCT00004010 | Lymphoma | bleomycin sulfa... filgrastim ABVD regimen cyclophosphamid... dacarbazine doxorubicin hyd... etoposide prednisone procarbazine hy... vinblastine sul... vincristine sul... radiation thera... | - 21 Years | Children's Oncology Group | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma | NCT01152788 | Melanoma | rIL-21 Dacarbazine | 18 Years - | Canadian Cancer Trials Group | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | NCT05922904 | Hodgkin Lymphom... | Brentuximab ved... Doxorubicin Hyd... Pembrolizumab Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy | NCT00257205 | Melanoma | dacarbazine CP-675,206 temozolomide | 18 Years - | AstraZeneca | |
| Treatment for Classical Hodgkin Lymphoma in Children and Adolescents | NCT02797717 | Classical Hodgk... | Radiotherapy: Vincristine Etoposide Prednisone Doxorubicin Dacarbazine Cyclophosphamid... | 1 Month - 18 Years | Rabin Medical Center | |
| Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00002669 | Melanoma (Skin) | aldesleukin recombinant int... cisplatin dacarbazine | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | NCT01404936 | Lymphoma | Interferon-2A Adriamycin Bleomycin Velban Dacarbazine | - | M.D. Anderson Cancer Center | |
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma | NCT00837148 | Sarcoma Synovial Sarcom... Leiomyosarcoma Malignant Perip... | Sorafenib and D... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | NCT01404936 | Lymphoma | Interferon-2A Adriamycin Bleomycin Velban Dacarbazine | - | M.D. Anderson Cancer Center | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | NCT01343277 | Advanced Liposa... | Trabectedin Dacarbazine | 15 Years - | Janssen Research & Development, LLC | |
| Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | NCT00410631 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... conventional su... peripheral bloo... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | NCT03016819 | Alveolar Soft P... Leiomyosarcoma Synovial Sarcom... Soft-Tissue Sar... | AL3818 Dacarbazine AL3818 or place... | 18 Years - | Advenchen Laboratories, LLC | |
| Prospective Study on HIV-related Hodgkin Lymphoma | NCT01468740 | HIV-associated ... | Doxorubicin Bleomycin Vinblastine Dacarbazine Etoposide Cyclophosphamid... Vincristine Procarbazine Prednisone | 18 Years - 75 Years | Harlachinger Krebshilfe e.V. | |
| Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | NCT00017225 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide ifosfamide melphalan tretinoin vincristine sul... vindesine autologous bone... conventional su... peripheral bloo... radiation thera... | - 20 Years | National Cancer Institute (NCI) | |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | NCT05987332 | Metastatic Uvea... | IDE196 Crizotinib Pembrolizumab Ipilimumab Nivolumab Dacarbazine | 18 Years - | IDEAYA Biosciences | |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | NCT02181738 | Hodgkin Disease | Nivolumab Doxorubicin Vinblastine Dacarbazine | 18 Years - | Bristol-Myers Squibb | |
| Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | NCT03712202 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... Lymphocyte-Rich... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Bleomycin Brentuximab Ved... Dacarbazine Doxorubicin Nivolumab Quality-of-Life... Vinblastine | 16 Years - | City of Hope Medical Center | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma | NCT00802880 | Sarcoma | Dacarbazine | 18 Years - | Washington University School of Medicine | |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | NCT02181738 | Hodgkin Disease | Nivolumab Doxorubicin Vinblastine Dacarbazine | 18 Years - | Bristol-Myers Squibb | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | NCT01771107 | AIDS-Related Ho... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... HIV Infection | Brentuximab Ved... Dacarbazine Doxorubicin Hyd... Pharmacological... Vinblastine | 18 Years - | National Cancer Institute (NCI) | |
| A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | NCT00600496 | Breast Cancer Breast Neoplasm... Colon Cancer Colonic Cancer Colon Neoplasms Lung Cancer Melanoma Kidney Cancer | AZD6244 Dacarbazine Erlotinib Docetaxel Temsirolimus | 18 Years - 130 Years | AstraZeneca | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | NCT00003389 | Lymphoma | Doxorubicin Bleomycin Vinblastine Dacarbazine Vincristine Mechlorethamine Etoposide Prednisone Cyclophosphamid... Radiotherapy | 16 Years - | Eastern Cooperative Oncology Group | |
| A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | NCT01006980 | Malignant Melan... | Vemurafenib Dacarbazine | 18 Years - | Hoffmann-La Roche | |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | NCT05922904 | Hodgkin Lymphom... | Brentuximab ved... Doxorubicin Hyd... Pembrolizumab Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | NCT01251107 | Hodgkin Lymphom... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Doxorubicin Bleomycin Vinblastine Dacarbazine | 17 Years - 60 Years | Fondazione Michelangelo | |
| Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) | NCT00091572 | Melanoma | Temozolomide Dacarbazine | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | NCT00369681 | Lymphoma | Bleomycin Rituximab Dacarbazine Doxorubicin Vinblastine | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | NCT00864253 | Malignant Melan... | ABI-007 Dacarbazine | 18 Years - | Celgene | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | NCT03233347 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... | Brentuximab Ved... Dacarbazine Doxorubicin Laboratory Biom... Nivolumab Vinblastine | 18 Years - 60 Years | Academic and Community Cancer Research United | |
| Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | NCT03517137 | Advanced Hodgki... | Brentuximab Ved... Adriamycin Vinblastine Dacarbazine Etoposide Cyclophosphamid... Radiation Thera... | 18 Years - 60 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | NCT02545075 | Melanoma | Ipilimumab Dacarbazine | 18 Years - | Bristol-Myers Squibb | |
| A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | NCT01721746 | Unresectable or... | BMS-936558 Dacarbazine Carboplatin Paclitaxel | 18 Years - | Bristol-Myers Squibb | |
| Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma | NCT00130442 | Melanoma | PI-88 and dacar... dacarbazine or ... | 18 Years - | Cellxpert Biotechnology Corp. | |
| A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma | NCT01692678 | Advanced or Met... | Trabectedin Dacarbazine | 15 Years - | Xian-Janssen Pharmaceutical Ltd. | |
| Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma | NCT00526318 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma | NCT01721772 | Melanoma | BMS-936558 (Niv... Placebo matchin... Dacarbazine Placebo matchin... | 18 Years - | Bristol-Myers Squibb | |
| A Phase I/II Study of Dasatinib and Dacarbazine | NCT00597038 | Metastatic Mela... | Dasatinib and D... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | NCT03070392 | Uveal Melanoma | IMCgp100 Dacarbazine Ipilimumab Pembrolizumab | 18 Years - 99 Years | Immunocore Ltd | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma | NCT00023738 | Sarcoma | filgrastim dacarbazine doxorubicin hyd... ifosfamide semaxanib conventional su... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | NCT02181738 | Hodgkin Disease | Nivolumab Doxorubicin Vinblastine Dacarbazine | 18 Years - | Bristol-Myers Squibb | |
| A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | NCT01721746 | Unresectable or... | BMS-936558 Dacarbazine Carboplatin Paclitaxel | 18 Years - | Bristol-Myers Squibb | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma | NCT00023738 | Sarcoma | filgrastim dacarbazine doxorubicin hyd... ifosfamide semaxanib conventional su... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery | NCT01835145 | Recurrent Uveal... Stage III Uveal... Stage IIIA Uvea... Stage IIIB Uvea... Stage IIIC Uvea... Stage IV Uveal ... | Cabozantinib S-... Dacarbazine Laboratory Biom... Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor | NCT03023124 | Solitary Fibrou... | Trabectedin Adriamycin Dacarbazine | 18 Years - | Italian Sarcoma Group | |
| Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | NCT00654732 | Classic Hodgkin... Lugano Classifi... Lugano Classifi... | Bleomycin Dacarbazine Doxorubicin Hyd... Rituximab Vinblastine | 17 Years - | M.D. Anderson Cancer Center | |
| PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | NCT03226249 | Classical Hodgk... Lymphocyte-Depl... Lymphocyte-Rich... Mixed Cellulari... Nodular Scleros... | Computed Tomogr... Dacarbazine Doxorubicin Hyd... Fludeoxyglucose... Laboratory Biom... Pembrolizumab Positron Emissi... Vinblastine Sul... | 18 Years - | Northwestern University | |
| CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma | NCT04727242 | LMS - Leiomyosa... Uterine Leiomyo... | Gemcitabine Dacarbazine Cytoreductive S... Functional Asse... Computed Tomogr... Gadolinium | 18 Years - | Stanford University | |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | NCT05675410 | Lugano Classifi... | Biospecimen Col... Bleomycin Sulfa... Brentuximab Ved... Computed Tomogr... Cyclophosphamid... Dacarbazine Doxorubicin Hyd... Etoposide Etoposide Phosp... Fludeoxyglucose... Involved-site R... Magnetic Resona... Nivolumab Positron Emissi... Prednisolone Prednisone Procarbazine Hy... Questionnaire A... Vinblastine Sul... Vincristine Sul... | 5 Years - 60 Years | National Cancer Institute (NCI) | |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | NCT06164275 | Classic Hodgkin... | Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine | 18 Years - | Northwestern University | |
| Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | NCT00580320 | Melanoma Soft Tissue Sar... Parathyroid Car... Small Cell Carc... Carcinoid Tumor... | Dacarbazine and... | 18 Years - | Virginia Commonwealth University | |
| S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma | NCT00822120 | Lymphoma Nonneoplastic C... | bleomycin sulfa... filgrastim ABVD regimen BEACOPP regimen cyclophosphamid... dacarbazine doxorubicin hyd... etoposide prednisone procarbazine hy... vinblastine sul... vincristine sul... | 18 Years - 60 Years | SWOG Cancer Research Network | |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | NCT06164275 | Classic Hodgkin... | Biopsy Biospecimen Col... Computed Tomogr... Dacarbazine Doxorubicin Echocardiograph... Multigated Acqu... Pembrolizumab Positron Emissi... Vinblastine | 18 Years - | Northwestern University | |
| Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 | NCT00070343 | Melanoma (Skin) | oblimersen sodi... dacarbazine | - | National Cancer Institute (NCI) | |
| Thalidomide and Dacarbazine for Metastatic Melanoma | NCT00006200 | Melanoma | thalidomide dacarbazine | 18 Years - | National Center for Research Resources (NCRR) | |
| A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | NCT01712490 | Hodgkin Lymphom... | brentuximab ved... doxorubicin bleomycin vinblastine dacarbazine | 18 Years - | Takeda | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Rituximab and ABVD for Hodgkin's Patients | NCT00504504 | Lymphoma | Rituximab Adriamycin Bleomycin Vinblastine Dacarbazine (DT... | 16 Years - | M.D. Anderson Cancer Center | |
| A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma | NCT02076646 | Metastatic Mela... | L19IL2 - Ph I L19IL2 at RD - ... DTIC | 18 Years - 70 Years | Philogen S.p.A. | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | NCT00518895 | Melanoma | dacarbazine plu... dacarbazine plu... | 18 Years - | Genta Incorporated | |
| Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | NCT05008224 | Classical Hodgk... | Pembrolizumab Doxorubicin Vinblastine Dacarbazine Bleomycin Etoposide Cyclophosphamid... Vincristine Procarbazine Prednisone | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
